Savla Chintan, Munoz Carlos, Hickey Richard, Belicak Maria, Gilbert Christopher, Cabrales Pedro, Palmer Andre F
William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.
Department of Bioengineering, University of California, San Diego, La Jolla, California, USA.
ACS Biomater Sci Eng. 2020 Sep 14;6(9):4957-4968. doi: 10.1021/acsbiomaterials.0c01146. Epub 2020 Aug 11.
Oxygen therapeutics are being developed for a variety of applications in transfusion medicine. In order to reduce the side-effects (vasoconstriction, systemic hypertension, and oxidative tissue injury) associated with previous generations of oxygen therapeutics, new strategies are focused on increasing the molecular diameter of hemoglobin obtained from mammalian sources via polymerization and encapsulation. Another approach towards oxygen therapeutic design has centered on using naturally occurring large molecular diameter hemoglobins (i.e. erythrocruorins) derived from annelid sources. Therefore, the goal of this study was to purify erythrocruorin from the terrestrial worm for diverse oxygen therapeutic applications. Tangential flow filtration (TFF) was used as a scalable protein purification platform to obtain a >99% pure LtEc product, which was confirmed by size exclusion high performance liquid chromatography and SDS-PAGE analysis. characterization concluded that the ultra-pure LtEc product had oxygen equilibrium properties similar to human red blood cells, and a lower rate of auto-oxidation compared to human hemoglobin, both of which should enable efficient oxygen transport under physiological conditions evaluation concluded that the ultra-pure product had positive effects on the microcirculation sustaining functional capillary density compared to a less pure product (~86% purity). In summary, we purified an LtEc product with favorable biophysical properties that performed well in an animal model using a reliable and scalable purification platform to eliminate undesirable proteins.
氧疗法正在输血医学的多种应用中进行研发。为了减少与前代氧疗法相关的副作用(血管收缩、全身性高血压和氧化组织损伤),新策略聚焦于通过聚合和封装增加从哺乳动物来源获得的血红蛋白的分子直径。氧疗法设计的另一种方法集中在使用源自环节动物来源的天然大分子直径血红蛋白(即蚯蚓血红蛋白)。因此,本研究的目标是从蚯蚓中纯化蚯蚓血红蛋白,用于多种氧疗法应用。切向流过滤(TFF)被用作一种可扩展的蛋白质纯化平台,以获得纯度>99%的LtEc产品,这通过尺寸排阻高效液相色谱和SDS-PAGE分析得到证实。表征得出结论,超纯LtEc产品具有与人类红细胞相似的氧平衡特性,并且与人类血红蛋白相比具有较低的自氧化速率,这两者都应能在生理条件下实现高效的氧运输。评估得出结论,与纯度较低的产品(~86%纯度)相比,超纯产品对维持功能性毛细血管密度的微循环有积极影响。总之,我们使用可靠且可扩展的纯化平台纯化了一种具有良好生物物理特性的LtEc产品,该产品在动物模型中表现良好,可去除不需要的蛋白质。